{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:01:55Z","timestamp":1787022115260,"version":"build-2736575974"},"reference-count":41,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T00:00:00Z","timestamp":1670544000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Real world effectiveness, toxicity and costs analyses from chimeric antigen receptor (CAR)-T cell therapy are of utmost relevance to determine whether and how to offer patients highly personalized immunotherapy. In this study, we aimed at describing CAR T-cells effectiveness, safety and costs in a Portuguese Comprehensive Cancer Center. We performed a retrospective descriptive study of adult patients with relapsed\/refractory diffuse large B-cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma and transformed follicular lymphoma referred to CAR T-cell therapy, between May 2019 and February 2021. Rates of treatment response, toxicity and survival (Kaplan-Meier method) were analyzed by intention-to-treat. Direct medical costs stratified by inpatient-care, outpatient-care, and diagnostic-therapeutic procedures (DTP) were derived based on resources used and their respective unit costs. In twenty patients (median age 49.5y; 55%male; 70%DLBCL; 50% with primary refractory disease), best overall and complete response rates were 65.0% and 45.0%, respectively. Median overall (OS) and progression-free survivals were 9.2 and 7.3 months; 12-month OS rate was 42.6% (95%CI:23.2\u201378.3). Grade\u22653 cytokine release syndrome and neurotoxicity occurred in 5.6% and 11.1% of patients, respectively. CAR T-cell therapy expenditure, including adverse events costs, was 7 176 196\u20ac, or 286 238\u20ac when excluding drug cost. Median cost for treated patient was 355 165\u20ac with CAR T-cell drug cost accounting for 97.0% of the overall expense. Excluding CAR T-cell acquisition cost, inpatient-care and DTP accounted for 57% and 38% of total cost\/patient, respectively. Our findings highlight the heavy economic burden of CAR T-cell therapy driven by drug acquisition costs.<\/jats:p>","DOI":"10.1371\/journal.pone.0278950","type":"journal-article","created":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T13:33:00Z","timestamp":1670592780000},"page":"e0278950","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":28,"title":["Costs, effectiveness, and safety associated with Chimeric Antigen Receptor (CAR) T-cell therapy: Results from a comprehensive cancer center"],"prefix":"10.1371","volume":"17","author":[{"given":"S\u00e9rgio","family":"Chacim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4944-3366","authenticated-orcid":true,"given":"Teresa","family":"Monjardino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Lu\u00eds","family":"Cunha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Medeiros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patr\u00edcia","family":"Redondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Jos\u00e9","family":"Bento","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 M\u00e1rio","family":"Mariz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2022,12,9]]},"reference":[{"issue":"6230","key":"pone.0278950.ref001","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1126\/science.aaa4967","article-title":"Adoptive cell transfer as personalized immunotherapy for human cancer","volume":"348","author":"SA Rosenberg","year":"2015","journal-title":"Science"},{"issue":"6382","key":"pone.0278950.ref002","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"O June CH","year":"2018","journal-title":"Science"},{"issue":"26","key":"pone.0278950.ref003","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"SS Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"27","key":"pone.0278950.ref004","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.19.02104","article-title":"Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium.","volume":"38","author":"LJ Nastoupil","year":"2020","journal-title":"J Clin Oncol."},{"issue":"27","key":"pone.0278950.ref005","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1200\/JCO.19.02103","article-title":"Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity.","volume":"38","author":"CA Jacobson","year":"2020","journal-title":"J Clin Oncol."},{"issue":"3","key":"pone.0278950.ref006","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1177\/1060028020944233","article-title":"Axicabtagene Ciloleucel: Clinical Data for the Use of CAR T-cell Therapy in Relapsed and Refractory Large B-cell Lymphoma","volume":"55","author":"Z Halford","year":"2021","journal-title":"Ann Pharmacother"},{"issue":"1","key":"pone.0278950.ref007","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"380","author":"SJ Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"10","key":"pone.0278950.ref008","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","article-title":"Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study.","volume":"22","author":"SJ Schuster","year":"2021","journal-title":"Lancet Oncol"},{"issue":"2","key":"pone.0278950.ref009","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.tmrv.2019.01.005","article-title":"Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis.","volume":"33","author":"EJM Grigor","year":"2019","journal-title":"Transfus Med Rev"},{"key":"pone.0278950.ref010","doi-asserted-by":"crossref","first-page":"698607","DOI":"10.3389\/fonc.2021.698607","article-title":"Efficacy and Safety of CAR-T Cell Products Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel for the Treatment of Hematologic Malignancies: A Systematic Review and Meta-Analysis.","volume":"11","author":"J Meng","year":"2021","journal-title":"Front Oncol."},{"issue":"2","key":"pone.0278950.ref011","doi-asserted-by":"crossref","first-page":"e524","DOI":"10.1097\/HS9.0000000000000524","article-title":"Health Economic Aspects of Chimeric Antigen Receptor T-cell Therapies for Hematological Cancers","volume":"5","author":"R Heine","year":"2021","journal-title":"Present and Future. Hemasphere"},{"issue":"7","key":"pone.0278950.ref012","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1001\/jamaoncol.2018.0977","article-title":"Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy.","volume":"4","author":"I Hernandez","year":"2018","journal-title":"JAMA Oncol"},{"key":"pone.0278950.ref013","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/hon.2595","article-title":"Managing the toxicities of CAR T-cell therapy.","volume":"371","author":"SS Neelapu","year":"2019","journal-title":"Hematol Oncol."},{"issue":"4","key":"pone.0278950.ref014","doi-asserted-by":"crossref","first-page":"e202072","DOI":"10.1001\/jamanetworkopen.2020.2072","article-title":"Economic Evaluation of Chimeric Antigen Receptor T-Cell Therapy by Site of Care Among Patients With Relapsed or Refractory Large B-Cell Lymphoma.","volume":"3","author":"GH Lyman","year":"2020","journal-title":"JAMA Netw Open"},{"key":"pone.0278950.ref015","first-page":"963689720919434","article-title":"Factors Associated with Costs in Chimeric Antigen Receptor T-Cell Therapy for Patients with Relapsed\/Refractory B-Cell Malignancies","volume":"29","author":"F Zhu","year":"2020","journal-title":"Cell Transplant"},{"issue":"5","key":"pone.0278950.ref016","first-page":"192","article-title":"Economic Burden of Neurologic Toxicities Associated with Treatment of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma in the United States.","volume":"13","author":"MS Broder","year":"2020","journal-title":"Am Health Drug Benefits."},{"issue":"13 Suppl","key":"pone.0278950.ref017","first-page":"S253","article-title":"Improving outcomes and mitigating costs associated with CAR T-cell therapy.","volume":"27","author":"R. Borgert","year":"2021","journal-title":"Am J Manag Care."},{"issue":"8","key":"pone.0278950.ref018","doi-asserted-by":"crossref","first-page":"928","DOI":"10.6004\/jnccn.2020.7678","article-title":"Healthcare Utilization and End-of-Life Outcomes in Patients Receiving CAR T-Cell Therapy.","volume":"19","author":"PC Johnson","year":"2021","journal-title":"J Natl Compr Canc Netw."},{"issue":"6","key":"pone.0278950.ref019","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.jval.2019.03.012","article-title":"Analytic Considerations in Applying a General Economic Evaluation Reference Case to Gene Therapy.","volume":"22","author":"MF Drummond","year":"2019","journal-title":"Value Health"},{"issue":"9","key":"pone.0278950.ref020","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1007\/s40273-021-01051-4","article-title":"Economic Evidence on Potentially Curative Gene Therapy Products: A Systematic Literature Review.","volume":"39","author":"JK Ho","year":"2021","journal-title":"Pharmacoeconomics"},{"issue":"10","key":"pone.0278950.ref021","doi-asserted-by":"crossref","first-page":"E844","DOI":"10.1001\/amajethics.2019.844","article-title":"How Should We Determine the Value of CAR T-Cell Therapy?","volume":"21","author":"S Silbert","year":"2019","journal-title":"AMA J Ethics."},{"issue":"5","key":"pone.0278950.ref022","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1080\/14737167.2019.1651646","article-title":"Is it a Chimera? A systematic review of the economic evaluations of CAR-T cell therapy","volume":"19","author":"P. Petrou","year":"2019","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"4","key":"pone.0278950.ref023","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1200\/JCO.19.01558","article-title":"Valuing Chimeric Antigen Receptor T-Cell Therapy: Current Evidence, Uncertainties, and Payment Implications.","volume":"38","author":"MD Whittington","year":"2020","journal-title":"J Clin Oncol."},{"issue":"9","key":"pone.0278950.ref024","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1080\/10428194.2022.2060503","article-title":"Real-world healthcare resource utilization and costs associated with tisagenlecleucel and axicabtagene ciloleucel among patients with diffuse large B-cell lymphoma: an analysis of hospital data in the United States","volume":"63","author":"RT Maziarz","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"27","key":"pone.0278950.ref025","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.","volume":"32","author":"BD Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"pone.0278950.ref026","author":"National Cancer Institute.","year":"2009","journal-title":"Common Terminology Criteria for Adverse Events v4.0 (CTCAE)."},{"issue":"4","key":"pone.0278950.ref027","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells.","volume":"25","author":"DW Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"pone.0278950.ref028","article-title":"Portaria n.\u00b0 207\/2017 de 11 de julho.","author":"Minist\u00e9rio da Sa\u00fade.","year":"2017","journal-title":"Di\u00e1rio da Rep\u00fablica n.\u00b0 132\/2017\u2014I S\u00e9rie."},{"issue":"9","key":"pone.0278950.ref029","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1038\/s41409-020-0956-8","article-title":"Value and affordability of CAR T-cell therapy in the United States","volume":"55","author":"S Fiorenza","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"pone.0278950.ref030","first-page":"163","article-title":"Barriers to Chimeric Antigen Receptor T-Cell (CAR-T) Therapies in Clinical Practice.","volume":"36","author":"A Gajra","year":"2022","journal-title":"Pharmaceut Med."},{"issue":"6","key":"pone.0278950.ref031","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.jval.2019.03.014","article-title":"Estimating the Clinical Pipeline of Cell and Gene Therapies and Their Potential Economic Impact on the US Healthcare System.","volume":"22","author":"C Quinn","year":"2019","journal-title":"Value Health"},{"key":"pone.0278950.ref032","volume":"18","author":"U.S. Department of Health and Human Services, Food and Drug Administration","year":"2022","journal-title":"FDA Approves First Cell-Based Gene Therapy for Adult Patients with Multiple Myeloma2021 Accessed"},{"key":"pone.0278950.ref033","article-title":"FDA grants accelerated approval to axicabtagene ciloleucel for relapsed or refractory follicular lymphoma2021","volume":"18","author":"U.S. Department of Health and Human Services, Food and Drug Administration.","year":"2022"},{"key":"pone.0278950.ref034","article-title":"FDA approves ciltacabtagene autoleucel for relapsed or refractory multiple myeloma2022","volume":"18","author":"U.S. Department of Health and Human Services, Food and Drug Administration.","year":"2022"},{"issue":"8","key":"pone.0278950.ref035","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1182\/blood-2018-04-839217","article-title":"Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed\/refractory diffuse large B-cell lymphoma","volume":"132","author":"VA Chow","year":"2018","journal-title":"Blood"},{"issue":"1","key":"pone.0278950.ref036","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial.","volume":"20","author":"FL Locke","year":"2019","journal-title":"Lancet Oncol"},{"issue":"3","key":"pone.0278950.ref037","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/bjh.18209","article-title":"A national service for delivering CD19 CAR-Tin large B-cell lymphoma\u2014The UK real-world experience","volume":"198","author":"A Kuhnl","year":"2022","journal-title":"Br J Haematol"},{"issue":"1","key":"pone.0278950.ref038","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s13613-022-01036-2","article-title":"The use of ICU resources in CAR-T cell recipients: a hospital-wide study","volume":"12","author":"S Valade","year":"2022","journal-title":"Ann Intensive Care"},{"key":"pone.0278950.ref039","article-title":"How much does the hospital stay for infusion of anti-CD19 CAR-T cells cost to the French National Health Insurance?","author":"M Huguet","year":"2021","journal-title":"Bull Cancer"},{"key":"pone.0278950.ref040","doi-asserted-by":"crossref","first-page":"253","DOI":"10.2147\/CEOR.S241880","article-title":"Cost-Effectiveness Analysis of Tisagenlecleucel in the Treatment of Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia in Children and Young Adults in Spain.","volume":"12","author":"JM Ribera Santasusana","year":"2020","journal-title":"Clinicoecon Outcomes Res."},{"issue":"24","key":"pone.0278950.ref041","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.18.02079","article-title":"Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Multiply Relapsed or Refractory Adult Large B-Cell Lymphoma.","volume":"37","author":"JK Lin","year":"2019","journal-title":"J Clin Oncol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0278950","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T13:33:17Z","timestamp":1670592797000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0278950"}},"subtitle":[],"editor":[{"given":"Yasunori","family":"Sato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,12,9]]},"references-count":41,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,12,9]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0278950","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,9]]}}}